The genetics of multiple sclerosis: An update 2010

Molecular and Cellular Probes

Volumn 24, Issue 5, 2010, Pages 237-243

  Hoffjan, Sabine ^a   Akkad, Denis A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Genome wide association; Multifactorial; Multiple sclerosis; Pharmacogenetics; Pharmacogenomics; Polymorphism

Indexed keywords

BETA INTERFERON; C TYPE LECTIN DOMAIN FAMILY 16 MEMBER A; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR ALPHA; LECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; NEUROTRANSMITTER TRANSPORTER; UNCLASSIFIED DRUG;

CANCER SUSCEPTIBILITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MULTIPLE SCLEROSIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN MICROARRAY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTIGENS, CD58; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; MONOSACCHARIDE TRANSPORT PROTEINS; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-7;

EID: 77956061262     PISSN: 08908508     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcp.2010.04.006     Document Type: Review

References (74)

1. Oksenberg J.R., Baranzini S.E., Sawcer S., Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008, 9:516-526.
2. Pugliatti M., Sotgiu S., Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002, 104:182-191.
3. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
4. Pugliatti M., Rosati G., Carton H., Riise T., Drulovic J., Vecsei L., et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006, 13:700-722.
5. Hawkes C.H., Macgregor A.J. Twin studies and the heritability of MS: a conclusion. Mult Scler 2009, 15:661-667.
6. Risch N., Merikangas K. The future of genetic studies of complex human diseases. Science 1996, 273:1516-1517.
7. Fernald G.H., Yeh R.F., Hauser S.L., Oksenberg J.R., Baranzini S.E. Mapping gene activity in complex disorders: integration of expression and genomic scans for multiple sclerosis. J Neuroimmunol 2005, 167:157-169.
8. Haines J.L., Terwedow H.A., Burgess K., Pericak-Vance M.A., Rimmler J.B., Martin E.R., et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The multiple sclerosis genetics group. Hum Mol Genet 1998, 7:1229-1234.
9. Hoffjan S., Nicolae D., Ober C. Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir Res 2003, 4:14.
10. Hindorff L.A., Sethupathy P., Junkins H.A., Ramos E.M., Mehta J.P., Collins F.S., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009, 106:9362-9367.
11. McCarthy M.I., Hirschhorn J.N. Genome-wide association studies: potential next steps on a genetic journey. Hum Mol Genet 2008, 17:R156-165.
12. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
13. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851-862.
14. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007, 39:1083-1091.
15. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007, 39:1108-1113.
16. Weber F., Fontaine B., Cournu-Rebeix I., Kroner A., Knop M., Lutz S., et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008, 9:259-263.
17. O'Doherty C., Kantarci O., Vandenbroeck K. IL7RA polymorphisms and susceptibility to multiple sclerosis. N Engl J Med 2008, 358:753-754.
18. Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., et al. The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis. Tissue Antigens 2008, 72:158-161.
19. Akkad D.A., Hoffjan S., Petrasch-Parwez E., Beygo J., Gold R., Epplen J.T. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J Autoimmun 2009, 32:110-115.
20. Johnson B.A., Wang J., Taylor E.M., Caillier S.J., Herbert J., Khan O.A., et al. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun Oct 2009, [Epub ahead of print].
21. Zuvich R.L., McCauley J.L., Oksenberg J.R., Sawcer S.J., De Jager P.L., Aubin C., et al. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 2010, 127(5):525-535.
22. Sasson S.C., Zaunders J.J., Kelleher A.D. The IL-7/IL-7 receptor axis: understanding its central role in T-cell homeostasis and the challenges facing its utilization as a novel therapy. Curr Drug Targets 2006, 7:1571-1582.
23. Rubio J.P., Stankovich J., Field J., Tubridy N., Marriott M., Chapman C., et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun 2008, 9:624-630.
24. Perera D., Stankovich J., Butzkueven H., Taylor B.V., Foote S.J., Kilpatrick T.J., et al. Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. J Neuroimmunol 2009, 211:105-109.
25. Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., et al. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS One 2009, 4:e4137.
26. Qu H.Q., Bradfield J.P., Belisle A., Grant S.F., Hakonarson H., Polychronakos C. The type I diabetes association of the IL2RA locus. Genes Immun 2009, 10(Suppl. 1):S42-48.
27. Kurreeman F.A., Daha N.A., Chang M., Catanese J.J., Begovich A.B., Huizinga T.W., et al. Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population. Ann Rheum Dis 2009, 68:1789-1790.
28. Hinks A., Ke X., Barton A., Eyre S., Bowes J., Worthington J., et al. Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:251-257.
29. Brand O.J., Lowe C.E., Heward J.M., Franklyn J.A., Cooper J.D., Todd J.A., et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf) 2007, 66:508-512.
30. Schippling D.S., Martin R. Spotlight on anti-CD25: daclizumab in MS. Int MS J 2008, 15:94-98.
31. De Jager P.L., Baecher-Allan C., Maier L.M., Arthur A.T., Ottoboni L., Barcellos L., et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A 2009, 106:5264-5269.
32. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009;41:824-828.
33. Hoppenbrouwers I.A., Aulchenko Y.S., Janssens A.C., Ramagopalan S.V., Broer L., Kayser M., et al. Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. J Hum Genet 2009, 54:676-680.
34. Hakonarson H., Grant S.F., Bradfield J.P., Marchand L., Kim C.E., Glessner J.T., et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007, 448:591-594.
35. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007, 39:857-864.
36. Zoledziewska M., Costa G., Pitzalis M., Cocco E., Melis C., Moi L., et al. Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun 2009, 10:15-17.
37. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 2009;10:11-14.
38. Marquez A., Varade J., Robledo G., Martinez A., Mendoza J.L., Taxonera C., et al. Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15(-) Crohn's disease patients. Eur J Hum Genet 2009, 17:1304-1308.
39. Skinningsrud B., Lie B.A., Husebye E.S., Kvien T.K., Forre O., Flato B., et al. A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-CCP negative rheumatoid arthritis. Ann Rheum Dis Sep 2009, [Epub ahead of print].
40. Awata T., Kawasaki E., Tanaka S., Ikegami H., Maruyama T., Shimada A., et al. Association of type 1 diabetes with two Loci on 12q13 and 16p13 and the influence coexisting thyroid autoimmunity in Japanese. J Clin Endocrinol Metab 2009, 94:231-235.
41. Skinningsrud B., Husebye E.S., Pearce S.H., McDonald D.O., Brandal K., Wolff A.B., et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J Clin Endocrinol Metab 2008, 93:3310-3317.
42. Hafler J.P., Maier L.M., Cooper J.D., Plagnol V., Hinks A., Simmonds M.J., et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 2008, 10:5-10.
43. Wieczorek S., Hoffjan S., Chan A., Rey L., Harper L., Fricke H., et al. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes Immun 2009, 10:591-595.
44. Dardalhon V., Schubart A.S., Reddy J., Meyers J.H., Monney L., Sabatos C.A., et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol 2005, 175:1558-1565.
45. Zhernakova A., van Diemen C.C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009, 10:43-55.
46. Sloka S. Observations on recent studies showing increased co-occurrence of autoimmune diseases. J Autoimmun 2002, 18:251-257.
47. Sloka J.S., Phillips P.W., Stefanelli M., Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis 2005, 2:9.
48. Rioux J.D., Goyette P., Vyse T.J., Hammarstrom L., Fernando M.M., Green T., et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 2009, 106:18680-18685.
49. Lettre G., Rioux J.D. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 2008, 17:R116-121.
50. Baranzini S.E. The genetics of autoimmune diseases: a networked perspective. Curr Opin Immunol 2009, 21:596-605.
51. Miller A., Avidan N., Tzunz-Henig N., Glass-Marmor L., Lejbkowicz I., Pinter R.Y., et al. Translation towards personalized medicine in multiple sclerosis. J Neurol Sci 2008, 274:68-75.
52. O'Doherty C., Villoslada P., Vandenbroeck K. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev 2007, 18:211-222.
53. Byun E., Caillier S.J., Montalban X., Villoslada P., Fernandez O., Brassat D., et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008, 65:337-344.
54. Cenit M.D., Blanco-Kelly F., de las Heras V., Bartolome M., de la Concha E.G., Urcelay E., et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 2009, 15:913-917.
55. Comabella M., Craig D.W., Morcillo-Suarez C., Rio J., Navarro A., Fernandez M., et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009, 66:972-978.
56. Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Hum Mol Genet 2010;19:953-962.
57. Baranzini S.E., Galwey N.W., Wang J., Khankhanian P., Lindberg R., Pelletier D., et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 2009, 18:2078-2090.
58. Munro K.M., Perreau V.M. Current and future applications of transcriptomics for discovery in CNS disease and injury. Neurosignals 2009, 17:311-327.
59. Mardis E.R. The impact of next-generation sequencing technology on genetics. Trends Genet 2008, 24:133-141.
60. Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med;362:1181-1191.
61. Roach J.C., Glusman G., Smit A.F., Huff C.D., Hubley R., Shannon P.T., et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 2010, 328:636-639.
62. McGuire A.L., Lupski J.R. Personal genome research: what should the participant be told?. Trends Genet 2010, 26:199-201.
63. De Jager P.L., Chibnik L.B., Cui J., Reischl J., Lehr S., Simon K.C., et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009, 8:1111-1119.
64. Corvol J.C., Pelletier D., Henry R.G., Caillier S.J., Wang J., Pappas D., et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A 2008, 105:11839-11844.
65. Comabella M., Craig D.W., Camina-Tato M., Morcillo C., Lopez C., Navarro A., et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One 2008, 3:e3490.
66. Aulchenko Y.S., Hoppenbrouwers I.A., Ramagopalan S.V., Broer L., Jafari N., Hillert J., et al. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 2008, 40:1402-1403.
67. Jakkula E, Leppa V, Sulonen AM, Varilo T, Kallio S, Kemppinen A, et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet;86:285-291.
68. De Jager P.L., Jia X., Wang J., de Bakker P.I., Ottoboni L., Aggarwal N.T., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009, 41:776-782.
69. Santiago J.L., Alizadeh B.Z., Martinez A., Espino L., de la Calle H., Fernandez-Arquero M., et al. Study of the association between the CAPSL-IL7R locus and type 1 diabetes. Diabetologia 2008, 51:1653-1658.
70. O'Doherty C., Alloza I., Rooney M., Vandenbroeck K. IL7RA polymorphisms and chronic inflammatory arthropathies. Tissue Antigens 2009, 74:429-431.
71. Raychaudhuri S., Thomson B.P., Remmers E.F., Eyre S., Hinks A., Guiducci C., et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009, 41:1313-1318.
72. Douroudis K., Nemvalts V., Rajasalu T., Kisand K., Uibo R. The CD226 gene in susceptibility of type 1 diabetes. Tissue Antigens 2009, 74:417-419.
73. Lappalainen M., Halme L., Turunen U., Saavalainen P., Einarsdottir E., Farkkila M., et al. Association of IL23R, TNFRSF1A, and HLA-DRB10103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm Bowel Dis 2008, 14:1118-1124.
74. Lu L.Y., Keng H.M., Chu J.J., Lin X.T., Hsu C.M., Sung P.K. TNF receptor I polymorphism is associated with persistent palindromic rheumatism. Scand J Rheumatol 2007, 36:278-284.